HVO - Ticker AI Digest

hVIVO plc 📰 1
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
hVIVO plc in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
HVO Data 2026-01-29 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (HVO) 1
HVO 06:01
hVIVO plc
Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
hVIVO plc, a full-service early-phase Contract Research Organisation (CRO) and leader in human challenge clinical trials, released a trading update for FY25 (year ended 31 December 2025). Key highlights include
1. **Financial Performance**
Revenue of approximately £46.7 million, in line with expectations (FY24: £62.7 million).
Positive low single-digit adjusted EBITDA margin, exceeding guidance (FY24: 26.2%).
Cash position of £14.3 million, debt-free, and ahead of expectations (FY24: £44.2 million).
2. **Strategic Acquisitions**
Completed and integrated acquisitions of CRS Mannheim & Kiel and Cryostore, creating an end-to-end early clinical development platform from preclinical to Phase III.
Four integrated service lines now fully operational: Consulting, Clinical Trials, Human Challenge Trials (HCTs), and Laboratories.
3. **Market Position and Pipeline**
FY25 faced macroeconomic and sector-specific challenges, including programme deferrals and cancellations in HCTs.
Strong momentum in FY26 pipeline across all service lines, with increasing opportunities in infectious diseases and diversified therapeutic areas (e.g., cardiometabolic, respiratory, immunology).
Aggregate value of customer proposals in FY25 exceeded FY24, indicating positive medium-term revenue growth.
4. **Outlook**
Reiterated guidance for high single-digit revenue growth in 2026.
Focus on four key growth initiativesexpanding therapeutic specialisms, enhancing laboratory services, and improving patient recruitment.
Confidence in full-service platform to drive near and long-term growth.
5. **Investor Engagement**
CEO Yamin Mo Khan and CFO Stephen Pinkerton hosted an investor meeting via Investor Meet Company to discuss the update.
hVIVO is well-positioned for growth in 2026, leveraging its diversified service offerings and strengthened infrastructure.
Below is the HTML table code comparing the financials and debt year-on-year for hVIVO PLC based on the provided text:
MetricFY2024FY2025
Revenue (£ million)62.746.7
Adjusted EBITDA Margin26.2%Positive low single-digit
Cash Position (£ million)44.214.3
DebtNoneNone
### Explanation: - **Revenue**: FY2024 revenue was £62.7 million, while FY2025 is expected to be £46.7 million. - **Adjusted EBITDA Margin**: FY2024 was 26.2%, and FY2025 is expected to be a positive low single-digit percentage. - **Cash Position**: Cash decreased from £44.2 million in FY2024 to £14.3 million in FY2025, primarily due to strategic acquisitions. - **Debt**: The company remains debt-free in both years. This table provides a clear year-on-year comparison of key financial metrics for hVIVO PLC.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 2
HVO 06:01
hVIVO plc
Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
hVIVO plc, a full-service early-phase Contract Research Organisation (CRO) and leader in human challenge clinical trials, released a trading update for FY25 (year ended 31 December 2025). Key highlights include
1. **Financial Performance**
Revenue of approximately £46.7 million, in line with expectations (FY24: £62.7 million).
Positive low single-digit adjusted EBITDA margin, exceeding guidance (FY24: 26.2%).
Cash position of £14.3 million, debt-free, and ahead of expectations (FY24: £44.2 million).
2. **Strategic Acquisitions**
Completed and integrated acquisitions of CRS Mannheim & Kiel and Cryostore, creating an end-to-end early clinical development platform from preclinical to Phase III.
Four integrated service lines now fully operational: Consulting, Clinical Trials, Human Challenge Trials (HCTs), and Laboratories.
3. **Market Position and Pipeline**
FY25 faced macroeconomic and sector-specific challenges, including programme deferrals and cancellations in HCTs.
Strong momentum in FY26 pipeline across all service lines, with increasing opportunities in infectious diseases and diversified therapeutic areas (e.g., cardiometabolic, respiratory, immunology).
Aggregate value of customer proposals in FY25 exceeded FY24, indicating positive medium-term revenue growth.
4. **Outlook**
Reiterated guidance for high single-digit revenue growth in 2026.
Focus on four key growth initiativesexpanding therapeutic specialisms, enhancing laboratory services, and improving patient recruitment.
Confidence in full-service platform to drive near and long-term growth.
5. **Investor Engagement**
CEO Yamin Mo Khan and CFO Stephen Pinkerton hosted an investor meeting via Investor Meet Company to discuss the update.
hVIVO is well-positioned for growth in 2026, leveraging its diversified service offerings and strengthened infrastructure.
Below is the HTML table code comparing the financials and debt year-on-year for hVIVO PLC based on the provided text:
MetricFY2024FY2025
Revenue (£ million)62.746.7
Adjusted EBITDA Margin26.2%Positive low single-digit
Cash Position (£ million)44.214.3
DebtNoneNone
### Explanation: - **Revenue**: FY2024 revenue was £62.7 million, while FY2025 is expected to be £46.7 million. - **Adjusted EBITDA Margin**: FY2024 was 26.2%, and FY2025 is expected to be a positive low single-digit percentage. - **Cash Position**: Cash decreased from £44.2 million in FY2024 to £14.3 million in FY2025, primarily due to strategic acquisitions. - **Debt**: The company remains debt-free in both years. This table provides a clear year-on-year comparison of key financial metrics for hVIVO PLC.
HVO 06:01
hVIVO plc
Notice of Trading Update
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 2
HVO 06:01
hVIVO plc
Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
hVIVO plc, a full-service early-phase Contract Research Organisation (CRO) and leader in human challenge clinical trials, released a trading update for FY25 (year ended 31 December 2025). Key highlights include
1. **Financial Performance**
Revenue of approximately £46.7 million, in line with expectations (FY24: £62.7 million).
Positive low single-digit adjusted EBITDA margin, exceeding guidance (FY24: 26.2%).
Cash position of £14.3 million, debt-free, and ahead of expectations (FY24: £44.2 million).
2. **Strategic Acquisitions**
Completed and integrated acquisitions of CRS Mannheim & Kiel and Cryostore, creating an end-to-end early clinical development platform from preclinical to Phase III.
Four integrated service lines now fully operational: Consulting, Clinical Trials, Human Challenge Trials (HCTs), and Laboratories.
3. **Market Position and Pipeline**
FY25 faced macroeconomic and sector-specific challenges, including programme deferrals and cancellations in HCTs.
Strong momentum in FY26 pipeline across all service lines, with increasing opportunities in infectious diseases and diversified therapeutic areas (e.g., cardiometabolic, respiratory, immunology).
Aggregate value of customer proposals in FY25 exceeded FY24, indicating positive medium-term revenue growth.
4. **Outlook**
Reiterated guidance for high single-digit revenue growth in 2026.
Focus on four key growth initiativesexpanding therapeutic specialisms, enhancing laboratory services, and improving patient recruitment.
Confidence in full-service platform to drive near and long-term growth.
5. **Investor Engagement**
CEO Yamin Mo Khan and CFO Stephen Pinkerton hosted an investor meeting via Investor Meet Company to discuss the update.
hVIVO is well-positioned for growth in 2026, leveraging its diversified service offerings and strengthened infrastructure.
Below is the HTML table code comparing the financials and debt year-on-year for hVIVO PLC based on the provided text:
MetricFY2024FY2025
Revenue (£ million)62.746.7
Adjusted EBITDA Margin26.2%Positive low single-digit
Cash Position (£ million)44.214.3
DebtNoneNone
### Explanation: - **Revenue**: FY2024 revenue was £62.7 million, while FY2025 is expected to be £46.7 million. - **Adjusted EBITDA Margin**: FY2024 was 26.2%, and FY2025 is expected to be a positive low single-digit percentage. - **Cash Position**: Cash decreased from £44.2 million in FY2024 to £14.3 million in FY2025, primarily due to strategic acquisitions. - **Debt**: The company remains debt-free in both years. This table provides a clear year-on-year comparison of key financial metrics for hVIVO PLC.
HVO 06:01
hVIVO plc
Notice of Trading Update

Today's AI

Today's AI Starts With News

1 live catalyst is opening Today’s AI for HVO.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2026-01-29 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
hVIVO plc has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
Single-Ticker Today's AI
HVO signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for hVIVO plc. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full HVO Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for HVO on 2026-01-29.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
59.5M
Enterprise Value
0
Public Float
83.0
Broker Target
16.929
Shares Out
688.4M
Long Interest
0
Short Interest
0
Exchange
LSE
Currency Code
GBX
ISIN
None
Market
None
Sector
Health Care Providers
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for HVO.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-01-29 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
hVIVO plc has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2025-05-15
Earnings Date
2026-04-08
Net Debt
490.0K
Cash
14.3M
EPS
-0.01
Net Income
-6.0M
Revenue
46.8M
Enterprise Value
0
Trailing PE
-
Forward PE
18.315
Price Sales TTM
1.1991
Price Book MRQ
1.6146
EV Revenue
1.3277
EV EBITDA
51.838
Financial Forecastist

Worsening financial engine

Revenue is accelerating +21.4% against the prior comparable period. Net margin is compressing by 40.2 pts. Net debt is coming down +102.0%.

Revenue +21.4% Net Income -323.8% FCF -1975.9% Current Ratio 1.63x Forward Rev 0
Worsening
Quarter Revenue
22.6M
+21.4%
vs prior comparable quarter
Net Margin
-26.1%
-40.2 pts
profitability pulse
Free Cash Flow
-7.4M
-1975.9%
cash conversion
Net Debt / EBITDA
-0.2x
-102.0%
lower is cleaner
Revenue Engine

Latest quarter printed 22.6M with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at -5.9M and the margin profile is tightening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 14.3M while net debt is 490.0K. The leverage stack is cleaning up.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2023
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q2 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q3 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
FY 2026
Consensus
50.4M
Revenue Path
-0.01
EPS / Earnings
Growth cue -0.2%
FY 2027
Consensus
54.9M
Revenue Path
-0.00
EPS / Earnings
Growth cue +0.7%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q4 2025 22.6M -5.9M -7.4M 490.0K
Q2 2025 25.4M -110.0K -8.1M -8.6M
Q4 2024 25.5M 5.4M 7.1M -31.3M
Q2 2024 37.2M 5.3M 788.0K -24.1M
Q1 2024 18.6M 2.6M 394.0K -
Q4 2023 30.0M 12.2M 5.8M -24.4M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 46.8M -6.0M 4.3M -14.8M
FY 2024 62.7M 10.7M 17.8M 7.9M
FY 2023 56.0M 16.1M 14.0M 12.1M
FY 2022 48.5M -776.0K 2.7M 14.6M
FY 2021 36.9M -74.0K 3.1M -2.3M

Structure DNA

Market Structure DNA

Income Anchor profile with trend broken

Price is -22.2% through the 52-week range, -87.5% vs 50DMA and -87.3% vs 200DMA. 37.7% of the register is locked by institutions and insiders, leaving 62.3% free float. Capital rhythm reads annual with forward yield near 2.1% and payout around 15.6%.

Trend broken Institutional gravity Reliable income rhythm As Of 2026-04-19
Income Anchor
Structure Score
47.4 / 100
Income Anchor
Trend Stack
-87.5% / -87.3%
vs 50DMA / 200DMA
52W Position
-22.2%
auction position inside the yearly range
Ownership Lock
37.7%
34.2% institutions | 3.5% insiders
Pressure Pocket
62.3% free float
Vendor short-float fields were not supplied
Capital Rhythm
Annual
Yield 2.1% | payout 15.6%
Trend Runway

Implied spot is 0.98 with the stock -87.5% vs 50DMA and -87.3% vs 200DMA. The tape is sitting -22.2% through the 52-week range, which frames the regime as trend broken.

Ownership Register

Institutions hold about 34.2% and insiders about 3.5%, locking roughly 37.7% of the register and leaving 62.3% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads annual with 1 event(s) in the last full year, a five-year average of 1.0, and stability score 100.0/100. Forward yield sits near 2.1% while payout is around 15.6%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

Annual
Year Dividend Count Context
2025 1 Full year
2024 1 Full year
2023 1 Full year

Structure Facts

Live Snapshot
Implied Spot
0.98
derived from market cap / shares
52W High
19.28
upper auction edge
52W Low
4.30
lower auction edge
Beta
1.67
volatility character
Shares Out
688.4M
fully diluted count
Shares Float
566.3M
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
2025-05-15
-339 day(s) to ex-date
Dividend Pay
-
payment date not supplied
Last Split
1:30
2012-12-14

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
24.1392
Institutions As Of
2026-06-09
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
1
Sale Director Dealing
1
Purchase TR1
8
Sale TR1
3
Broker Coverage Rows
0
Institution Holders Tracked
2
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for HVO, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-01-29 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
hVIVO plc has fresh news flow live now, so the tape is framing the chart workspace below.
AI Charts Studio
HVO Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-01-29 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast 57.42%
RSI Gauge
Price Change
AI Forecast